Literature DB >> 36066237

Multidrug-Resistant Gram-Negative Bacteria in Burn Patients.

Laura Ruegsegger1, Jamie Xiao1, Arash Naziripour1, Trey Kanumuambidi1, Dylan Brown1, Felicia Williams2, Steven H Marshall3, Susan D Rudin3,4, Kelly Yen5, Tingyu Chu5, Liang Chen5, Emanuele Sozzi6, Luther Bartelt1, Barry Kreiswirth5, Robert A Bonomo3,4,7,8, David van Duin1.   

Abstract

Patients with burn injuries are at high risk for infectious complications, and infections are the most common cause of death after the first 72 h of hospitalization. Hospital-acquired infections caused by multidrug resistant (MDR) Gram-negative bacteria (GNB) in this population are concerning. Here, we evaluated carriage with MDR GNB in patients in a large tertiary-care burn intensive care unit. Twenty-nine patients in the burn unit were screened for intestinal carriage. Samples were cultured on selective media. Median time from admission to the burn unit to first sample collection was 9 days (IQR 5 - 17 days). In 21 (72%) patients, MDR GNB were recovered; the most common bacterial species isolated was Pseudomonas aeruginosa, which was found in 11/29 (38%) of patients. Two of these patients later developed bloodstream infections with P. aeruginosa. Transmission of KPC-31-producing ST22 Citrobacter freundii was detected. Samples from two patients grew genetically similar C. freundii isolates that were resistant to ceftazidime-avibactam. On analysis of whole-genome sequencing, blaKPC-31 was part of a Tn4401b transposon that was present on two different plasmids in each C. freundii isolate. Plasmid curing experiments showed that removal of both copies of blaKPC-31 was required to restore susceptibility to ceftazidime-avibactam. In summary, MDR GNB colonization is common in burn patients and patient-to-patient transmission of highly resistant GNB occurs. These results emphasize the ongoing need for infection prevention and antimicrobial stewardship efforts in this highly vulnerable population.

Entities:  

Keywords:  Citrobacter; Pseudomonas aeruginosa; burn; carbapenemase; ceftazidime-avibactam; hospital infections; plasmid-mediated resistance

Mesh:

Substances:

Year:  2022        PMID: 36066237      PMCID: PMC9487463          DOI: 10.1128/aac.00688-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  39 in total

1.  SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing.

Authors:  Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner
Journal:  J Comput Biol       Date:  2012-04-16       Impact factor: 1.479

2.  In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Authors:  David M Livermore; Marina Warner; Dorota Jamrozy; Shazad Mushtaq; Wright W Nichols; Nazim Mustafa; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 3.  Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.

Authors:  Darren Wong; David van Duin
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

4.  The BioWipe: a non-invasive method to detect intestinal carriage of multi-drug resistant GRAM-negative bacteria.

Authors:  Emanuele Sozzi; Luther Bartelt; Jamie Xiao; Trey Kanumuambidi; Arash Naziripour; Laura Ruegsegger; Dylan Brown; Felicia Williams; Yuang Zhu; Xiao Bin Zhu; Tarun Prakash; Berkley Wood; Jatin Chandra Srivastava; Megan A Stallard; Steven H Marshall; Susan D Rudin; Mark D Sobsey; Robert A Bonomo; David van Duin
Journal:  J Chemother       Date:  2021-11-26       Impact factor: 1.714

5.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Brian A Potoski; Ghady Haidar; Binghua Hao; Yohei Doi; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2016-09-13       Impact factor: 9.079

Review 6.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

7.  An outbreak of multidrug-resistant Pseudomonas aeruginosa in a burns service in the North of England: challenges of infection prevention and control in a complex setting.

Authors:  V Decraene; S Ghebrehewet; E Dardamissis; R Huyton; K Mortimer; D Wilkinson; K Shokrollahi; S Singleton; B Patel; J Turton; P Hoffman; R Puleston
Journal:  J Hosp Infect       Date:  2018-09-11       Impact factor: 3.926

8.  Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae at a single institution: insights into endemicity from whole-genome sequencing.

Authors:  Amy J Mathers; Nicole Stoesser; Anna E Sheppard; Louise Pankhurst; Adam Giess; Anthony J Yeh; Xavier Didelot; Stephen D Turner; Robert Sebra; Andrew Kasarskis; Tim Peto; Derrick Crook; Costi D Sifri
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

9.  Trimmomatic: a flexible trimmer for Illumina sequence data.

Authors:  Anthony M Bolger; Marc Lohse; Bjoern Usadel
Journal:  Bioinformatics       Date:  2014-04-01       Impact factor: 6.937

10.  ResFinder 4.0 for predictions of phenotypes from genotypes.

Authors:  Valeria Bortolaia; Rolf S Kaas; Etienne Ruppe; Marilyn C Roberts; Stefan Schwarz; Vincent Cattoir; Alain Philippon; Rosa L Allesoe; Ana Rita Rebelo; Alfred Ferrer Florensa; Linda Fagelhauer; Trinad Chakraborty; Bernd Neumann; Guido Werner; Jennifer K Bender; Kerstin Stingl; Minh Nguyen; Jasmine Coppens; Basil Britto Xavier; Surbhi Malhotra-Kumar; Henrik Westh; Mette Pinholt; Muna F Anjum; Nicholas A Duggett; Isabelle Kempf; Suvi Nykäsenoja; Satu Olkkola; Kinga Wieczorek; Ana Amaro; Lurdes Clemente; Joël Mossong; Serge Losch; Catherine Ragimbeau; Ole Lund; Frank M Aarestrup
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.